Developing innovative new treatment options for the Autism community.
INDICATION
The autism community urgently needs better therapeutic options. Currently only two drugs are approved to address this condition, and both come with frequent adverse side effects.
Autism Spectrum Disorder (ASD)
THERAPY
DEFLORIA is a joint venture between Ajna BioSciences, Charlotte’s Web, and BAT dedicated to developing the first FDA-Approved, full spectrum botanical hemp extract specifically tailored to alleviate the symptoms of Autism Spectrum Disorder.
AJA001 - A Full Spectrum CBD Extract
By leveraging Charlotte’s Web’s patented genetics and an optimized formula designed for peak bioavailability, AJA001 has the potential to transform treatment for ASD by providing symptom relief for an enhanced quality of life, paving the way for brighter futures for both patients and families.
JOINT VENTURE HIGHLIGHTS
-
Leveraging Charlotte’s Web's premium proprietary hemp extracts and Ajna’s proven drug development expertise, DEFLORIA is poised to fulfill its mission with excellence and innovation.
-
Harnessing the therapeutic potential of CBD delivers healing benefits without the psychoactive implications commonly linked to cannabis. This serves as the cornerstone for expansive R&D and future applications.
-
Renowned entrepreneurs with a successful track record in the CBD wellness sector, guided by top-tier thought leaders including Orrin Devinsky, MD., world-renowned pediatric neurologist and lead principal investigator for Epidiolex™, the only FDA-approved CBD drug.
-
Upon FDA approval, DEFLORIA gains first mover advantage fortified by patent protection. Initiated 18 months ago, DEFLORIA’s program is poised to deliver the world’s first oral-systemic botanical drug.
ENTOURAGE EFFECT
A recent study indicates that all three of these component molecules found in AJA001 are likely important in treating ASD in the general population.
DEVELOPMENT TIMELINE
LEADERSHIP TEAM & BOARD
-
Orrin Devinsky, MD
Chief Medical Advisor - Ajna BioSciences, Director Comprehensive Epilepsy Center at NYU Langone. Formerly lead principal investigator for Epidiolex™.
-
Ryan Lanier, PhD
Chief Scientific Officer - DEFLORIA, 20+ years researching CNS compounds including cannabinoids & psychedelics. Expert in pharmaceutical product development from IND-enabling studies through Phase III clinical trials.
-
Marcel Bonn-Miller
DEFLORIA Board Member, Chief Scientific Officer - Charlotte’s Web, 20+ years of cannabinoid drug development expertise, including Zynerba Pharmaceuiticals and Canopy Growth Corporation.
-
Joel Stanley
DEFLORIA Board Chairman Co-founder Ajna BioSciences Former CEO & Board Chairman of Charlotte’s Web.
-
Donna Gutterman, PharmD, MBA
President at Onesta, Inc., 35+ years pharmaceutical industry experience (GSK) in developing, launching and commercialization of medicines in CNS therapeutic area.
-
Patrick Doyle
DEFLORIA Board Advisor, CEO at KBio & former CEO at Stelexis Therapeutics. 20+ years of leadership experience within pharmaceutical and biotech companies.
-
Bob Judge
DEFLORIA Board Member, VP Finance - Ajna BioSciences
-
Stephen Rogers
DEFLORIA Board Member, Senior Vice President, General Counsel, and Corporate Secretary at Charlotte’s Web
INVESTORS
Join us in leading change and creating hope for millions.
Our groundbreaking work has led us to the cusp of a medical breakthrough, and we invite you to be part of this revolutionary journey.
